Studies how sublingual apomorphine is dosed in Parkinson's disease
Observes real-world use and dose adjustment of sublingual apomorphine in adults with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment
Key facts
- Where
- Berlin, Bochum, Freiburg im Breisgau, Fulda, Hetzdorf, Osnabrück, Siegen, Sundern, Ulm, and Wusterhausen, GermanySee the 12 sites
Where in Germany
- Charité - Universitätsmedizin Berlin - Sektion für Bewegungsstörungen und NeuromodulationBerlin, GermanyTaking people
- Praxis für NeurologieBerlin, GermanyTaking people
- Alexianer St. Joseph Berlin-Weißensee GmbHBerlin, GermanyNo longer taking part
- Katholisches Klinikum Bochum gGmbH, Universitätsklinikum St.Josef-Hospital, Klinik für NeurologieBochum, GermanyNot yet recruiting
- UNIVERSITÄTSKLINIKUM FREIBURG - Neurozentrum Klinik für Neurologie und Neurophysiologie im NeurozentrumFreiburg im Breisgau, GermanyTaking people
- Praxis für Neurologie und PsychiatrieFulda, GermanyTaking people
- Klinik am Tharandter WaldHetzdorf, GermanyTaking people
- Klinik für Neurologie und Neurologische FrührehabilitationOsnabrück, GermanyTaking people
- Die Nerven DocsSiegen, GermanyTaking people
- Neurologische Klinik SorpeseeSundern, GermanyTaking people
- Praxis für Neurologie und GeriatrieUlm, GermanyTaking people
- Neurologie am FunkerbergWusterhausen, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bial - Portela C S.A.
- Trial code
- NCT07145190
- Record updated
- 11 August 2026
- Original description
The purpose of the study is to generate real-world evidence data for the on-demand treatment with SL-APO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment to ultimately understand their influence in patient satisfaction, treatment persistence, and the balance between effectiveness and safety. The data may help optimize titration approaches to better meet the patient's needs.Read full original descriptionShow less
SL-APO in the Treatment of Patients With Parkinson's Disease: a Real-world Evidence Study to Identify Titration and Usage Schemes - SL-START
The purpose of the study is to generate real-world evidence data for the on-demand treatment with SL-APO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment to ultimately understand their influence in patient satisfaction, treatment persistence, and the balance between effectiveness and safety. The data may help optimize titration approaches to better meet the patient's needs.
Inclusion: The patient is ≥ 18 years of age; The patient has a clinical diagnosis of idiopathic Parkinson's disease; The patient will initiate SL-APO for the treatment of OFF episodes according to the SmPC; The patient is not currently on titration or maintenance dose for SL-APO; The patient has provided written informed consent to participate in this study.
Exclusion: The patient is participating in a clinical trial with an investigational drug; The patient has presented with dementia or evidence of cognitive decline as determined by the investigator; The patient has a history of psychotic disorder; The patient presents any other contraindication according to the SL-APO SmPC.